We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alkermes Sinks as FDA Refuses to Approve Depression Drug
Read MoreHide Full Article
Alkermes Plc. (ALKS - Free Report) announced that the FDA has issued a Complete Response Letter (“CRL”) related to its new drug application (“NDA”) for ALKS 5461. The NDA sought approval for the candidate as an adjunctive treatment of major depressive disorder (“MDD”). The regulatory authority refused approval due to a lack of evidence supporting efficacy of the oral medication.
Importantly, the FDA requested for additional clinical data to demonstrate substantial evidence of effectiveness of ALKS 5461 for the proposed indication. The company is planning to meet with the FDA to discuss the issues raised in the CRL and future steps related to the development of ALKS 5461.
Shares of Alkermes fell 4.8% in after-hours trading on Feb 1 following the news. The company’s shares have fallen 26.6% in the past six months compared with the industry’s decline of 12.9%.
The decision was likely based on the fact that an advisory panel to the FDA had voted against approval of the drug in November. Moreover, the FDA had issued a Refusal to Accept letter in March 2017 during the submission of the NDA citing similar reason. However, the company appealed against the decision and the NDA was accepted in April.
Depression and other psychological disorders have been a tricky area for researchers with respect to developing treatments. There are only a few antipsychotic drugs, which are approved as add-on treatment for MDD, which includes AstraZeneca’s (AZN - Free Report) Seroquel.
Alkermes’ ALKS 5461 targets a significant market, which had approximately 16.2 million patients in the United States in 2016. The company stated that the majority of these patients are unlikely to have adequate response after initial treatment with antidepressants. The CRL is likely to delay or result in a missed opportunity for the company. The prospect of the candidate depends on the outcome of the company’s discussion with the FDA.
The company, however, has a strong pipeline of candidates targeting major central nervous system disorders. Alkermes is developing ALKS 3831 for schizophrenia and BIIB098 in collaboration with Biogen (BIIB - Free Report) for treating multiple sclerosis. In December, an NDA was filed with the FDA for BIIB098.
Galectin’s loss estimates have narrowed from 44 cents to 38 cents for 2018 and from $1.12 to 98 cents for 2019 over the past 60 days. The company delivered a positive earnings surprise in all the last four quarters, with the average beat being 18.65%. Share price of the company has risen 16.7% in the past year.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Alkermes Sinks as FDA Refuses to Approve Depression Drug
Alkermes Plc. (ALKS - Free Report) announced that the FDA has issued a Complete Response Letter (“CRL”) related to its new drug application (“NDA”) for ALKS 5461. The NDA sought approval for the candidate as an adjunctive treatment of major depressive disorder (“MDD”). The regulatory authority refused approval due to a lack of evidence supporting efficacy of the oral medication.
Importantly, the FDA requested for additional clinical data to demonstrate substantial evidence of effectiveness of ALKS 5461 for the proposed indication. The company is planning to meet with the FDA to discuss the issues raised in the CRL and future steps related to the development of ALKS 5461.
Shares of Alkermes fell 4.8% in after-hours trading on Feb 1 following the news. The company’s shares have fallen 26.6% in the past six months compared with the industry’s decline of 12.9%.
The decision was likely based on the fact that an advisory panel to the FDA had voted against approval of the drug in November. Moreover, the FDA had issued a Refusal to Accept letter in March 2017 during the submission of the NDA citing similar reason. However, the company appealed against the decision and the NDA was accepted in April.
Depression and other psychological disorders have been a tricky area for researchers with respect to developing treatments. There are only a few antipsychotic drugs, which are approved as add-on treatment for MDD, which includes AstraZeneca’s (AZN - Free Report) Seroquel.
Alkermes’ ALKS 5461 targets a significant market, which had approximately 16.2 million patients in the United States in 2016. The company stated that the majority of these patients are unlikely to have adequate response after initial treatment with antidepressants. The CRL is likely to delay or result in a missed opportunity for the company. The prospect of the candidate depends on the outcome of the company’s discussion with the FDA.
The company, however, has a strong pipeline of candidates targeting major central nervous system disorders. Alkermes is developing ALKS 3831 for schizophrenia and BIIB098 in collaboration with Biogen (BIIB - Free Report) for treating multiple sclerosis. In December, an NDA was filed with the FDA for BIIB098.
Alkermes plc Price
Alkermes plc Price | Alkermes plc Quote
Zacks Rank & Key Pick
Alkermes currently carries a Zacks Rank #2 (Buy). Galectin Therapeutics Inc. (GALT - Free Report) is another top-ranked stock from the healthcare space, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Galectin’s loss estimates have narrowed from 44 cents to 38 cents for 2018 and from $1.12 to 98 cents for 2019 over the past 60 days. The company delivered a positive earnings surprise in all the last four quarters, with the average beat being 18.65%. Share price of the company has risen 16.7% in the past year.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>